1684 completed, 511 recruiting, 485 unknown, 454 terminated. 2126 Phase 2, 1179 Phase 1, 691 Phase 3, 147 Not applicable, 71 Phase 4.
Follow Cyclophosphamide: new trials by email Literature Review of Cyclophosphamide trials Research Report on Cyclophosphamide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Open-label Study of GC012F in Rheumatoid Arthritis. LD and GC012F CAR-T Cell Injection, GC012F CAR-T Cell Injection - Rheumatoid Arthritis | Early Phase 1 | Withdrawn | Institute of Hematology & Blood Diseases Hospital, China | 2027-12-01 | 2026-06-10 | |
| Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography - Recurrent Ganglioneuroblastoma, Recurrent Neuroblastoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 76 | 2027-06-25 | 2026-10-22 |
| ²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma Allogeneic Hematopoietic Stem Cell Transplantation, Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10, Cyclophosphamide - Multiple Myeloma, Recurrent Multiple Myeloma | Phase 1 | Withdrawn | Fred Hutchinson Cancer Center | 2027-06-01 | 2026-09-11 | |
| Genetically Engineered Cells (BAFFR-CAR T Cells) for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Lymphoblastic Lymphoma Autologous BAFFR-targeting CAR T Cells, Biospecimen Collection, Bone Marrow Aspiration - Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma | Phase 1 | Not yet recruiting | City of Hope Medical Center | 16 | 2027-04-17 | 2026-08-11 |
| Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies C9/CD5CAR/IL-15 NK cells, Rituximab, Fludarabine - Hematological Malignancies | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 70 | 2027-02-28 | 2026-08-20 |
| Autologous Tumor Infiltrating Lymphocytes With Interleukin-2 for the Treatment of Locally Advanced, Recurrent or Metastatic Gastrointestinal Stromal Tumors Aldesleukin, Biospecimen Collection, Chest Radiography - Locally Advanced Gastrointestinal Stromal Tumor, Metastatic Gastrointestinal Stromal Tumor | Phase 2 | Not yet recruiting | Joal Beane | 59 | 2027-02-15 | 2026-10-13 |
| A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis BMS-986353, Fludarabine, Cyclophosphamide - Systemic Sclerosis | Phase 3 | Not yet recruiting | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 92 | 2027-02-03 | 2026-09-18 |
| Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome Allogeneic CD34+-enriched and CD45RA-depleted PBSCs, Biospecimen Collection, Bone Marrow Aspiration - Acute Biphenotypic Leukemia, Acute Leukemia | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 52 | 2027-01-01 | 2026-09-14 |
| A Trial to Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Standard of Care in Newly Diagnosed Multiple Myeloma Anitocabtagene autoleucel, Daratumumab, Bortezomib - Newly Diagnosed Multiple Myeloma | Phase 3 | Not yet recruiting | Kite, A Gilead Company | 600 | 2027-01-01 | 2026-10-21 |
| Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma Fludarabine, Cyclophosphamide, CD70.CAR NK Cells - Large B-cell Lymphoma, Hodgkin Lymphoma | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 100 | 2026-12-28 | 2026-07-15 |
| BSB-2002 After Cyclophosphamide and Fludarabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 Mutation Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 | Not yet recruiting | City of Hope Medical Center | 19 | 2026-12-14 | 2026-05-13 |
| Epcoritamab and Pola-R-mini-CHP for the Treatment of Diffuse Large B Cell Lymphoma in Elderly or Unfit Patients Biospecimen Collection, Computed Tomography, Cyclophosphamide - Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma | Phase 1 | Not yet recruiting | Jonsson Comprehensive Cancer Center | 20 | 2026-12-08 | 2026-07-20 |
| Study of Autologous, Metabolically Optimized, CD137+ Tumor-Infiltrating Lymphocytes Followed by Consolidative Oral Cyclophosphamide, Bevacizumab, and Pembrolizumab Fludarabine, Cyclophosphamide - Ovarian Cancer | Phase 2 | Not yet recruiting | Medical University of South Carolina | 20 | 2026-12-01 | 2026-07-22 |
| Lymphodepletion With Low Dose Total Body Irradiation Before Standard of Care Tisagenlecleucel for the Treatment of Relapsed and Recurrent Large B-cell Lymphoma Biospecimen Collection, Computed Tomography, Cyclophosphamide - Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Phase 1 | Recruiting | Nathan Denlinger | 18 | 2026-12-01 | 2026-10-09 |
| Study to Evaluate Change in Disease Activity and Adverse Events of Subcutaneous Etentamig Compared With Daratumumab Plus Cyclophosphamide Plus Bortezomib Plus Dexamethasone (Dara-CyBorD) in Adults With Amyloid Light Chain (AL) Amyloidosis Etentamig, Daratumumab, Cyclophosphamide - Amyloid Light Chain (AL) Amyloidosis | Phase 3 | Not yet recruiting | AbbVie | 370 | 2026-11-29 | 2026-08-28 |
| Autologous CAR T Cells Targeting GPC3 (RPCAR01) for the Treatment of Advanced or Metastatic GPC3 Expressing Hepatocellular Carcinoma Anti-GPC3-CAR Autologous T Lymphocytes, Biospecimen Collection, Computed Tomography - Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma | Phase 1 | Suspended | Roswell Park Cancer Institute | 24 | 2026-11-15 | 2026-09-15 |
| Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma Rituximab, Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisolone (R-CHOP), Epcoritamab, Dexamethasone - Non-Hodgkin's B-cell Lymphoma, Lymphoma Non-Hodgkin | Phase 2 | Not yet recruiting | Carrie Ho, MD | 20 | 2026-11-15 | 2026-10-01 |
| CSF-1R Inhibitor, Axatilimab, for Prevention of Acute and Chronic GVHD After HLA-Matched Related and Unrelated Donor Allogeneic Stem Cell Transplantation Hematopoietic Cell Transplantation, Cyclophosphamide, Tacrolimus - Graft -Versus-host-disease | Phase 2 | Not yet recruiting | Medical College of Wisconsin | 72 | 2026-11-01 | 2026-09-08 |
| Automated Total Marrow and Lymphoid Irradiation for Allogeneic Hematopoietic Cell Transplant VMAT-Based Total Marrow and Lymphoid Irradiation (TMLI), Fludarabine, Cyclophosphamide - Acute Myeloid Leukemia, Myeloproliferative Neoplasm | Phase 2 | Not yet recruiting | Stanford University | 30 | 2026-11-01 | 2026-09-30 |
| IL-18 Armored STEAP1 CAR T Cells for the Treatment of Metastatic Castration Resistant Prostate Cancer FH-STEAP1 IL-18 CAR T cells, Antiandrogen Therapy, Biospecimen Collection - Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 1 | Not yet recruiting | Fred Hutchinson Cancer Center | 20 | 2026-10-31 | 2026-09-04 |
Showing 20 of 3769. Sign in to see all of them.
Breast Neoplasms (557) · Lymphoma (449) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (413) · Lymphoma, Large B-Cell, Diffuse (355) · Leukemia (347) · Multiple Myeloma (339) · Lymphoma, Non-Hodgkin (320) · Leukemia, Myeloid, Acute (293) · Leukemia, Lymphocytic, Chronic, B-Cell (286) · Lymphoma, Follicular (243) · Myelodysplastic Syndromes (226) · Burkitt Lymphoma (223) · Lymphoma, Mantle-Cell (203) · Hodgkin Disease (193) · Recurrence (170)
National Cancer Institute (NCI) (215) · M.D. Anderson Cancer Center (174) · Children's Oncology Group (100) · Fred Hutchinson Cancer Center (92) · Masonic Cancer Center, University of Minnesota (80) · Memorial Sloan Kettering Cancer Center (80) · St. Jude Children's Research Hospital (71) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (70) · City of Hope Medical Center (60) · Hoffmann-La Roche (53) · SWOG Cancer Research Network (39) · Mayo Clinic (34) · Dana-Farber Cancer Institute (33) · Baylor College of Medicine (32) · Kite, A Gilead Company (32)
United States (2253) · China (542) · Canada (315) · Germany (267) · France (253) · United Kingdom (250) · Australia (235) · Italy (232) · Spain (215) · Netherlands (151) · Belgium (148) · Switzerland (130) · Poland (111) · South Korea (111) · Puerto Rico (102)
Steven A Rosenberg, M.D. (28) · Norman Wolmark, MD (15) · Richard Burt, MD (11) · Qifa Liu (10) · James N Kochenderfer, M.D. (9)
PMID 34515338, PMID 41671463, PMID 37505794, PMID 40135712, PMID 40207789, PMID 34037241, PMID 39121442, PMID 22555974, PMID 31221778, PMID 31401903, PMID 32450725, PMID 33357481, PMID 36240296, PMID 39319495, PMID 22508812, PMID 22689675, PMID 27282998, PMID 27641687, PMID 29567784, PMID 33242441, PMID 35622074, PMID 37890117, PMID 38603649, PMID 38979716, PMID 40501401, PMID 12171484, PMID 18997171, PMID 21403127, PMID 22430088, PMID 23007406, PMID 23861247, PMID 24970932, PMID 25310303, PMID 25628469, PMID 26101239, PMID 26373676, PMID 30714987, PMID 32747469, PMID 34252375, PMID 34778952, PMID 34870327, PMID 35882475, PMID 38335467, PMID 38446568, PMID 39058968, PMID 42133908, PMID 16105981, PMID 16236738, PMID 16421426, PMID 16790698
U10CA098543 (54), U10CA180886 (54), P30CA033572 (41), U10CA032102 (38), P30CA015704 (30), 2023 (27), P30CA006973 (27), 2016 (23), 2015 (20), P30CA043703 (20), U10CA031946 (20), P30CA015083 (18), P30CA016672 (18), 2017 (17), 2019 (17)